HilleVax, Inc. logo

HilleVax, Inc. (HLVX)

Delisted
17 Sep 2025
NASDAQ (NGS) NASDAQ (NGS)
$
2. 09
-0.01
-0.4762%
$
104.76M Market Cap
- P/E Ratio
- Div Yield
2.8M Volume
-3.02 Eps
$ 2.1
Previous Close
Day Range
2.09 2.09
Year Range
1.34 2.17
Want to track HLVX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Stakeholders Of HilleVax Inc Are Encouraged By The Schall Law Firm To Join The Alleged Securities Fraud Investigation

Stakeholders Of HilleVax Inc Are Encouraged By The Schall Law Firm To Join The Alleged Securities Fraud Investigation

LOS ANGELES, CA / ACCESSWIRE / July 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Accesswire | 2 years ago
Stakeholders Of HilleVax Inc Are Urged By The Schall Law Firm To Participate In The Alleged Securities Fraud Investigation

Stakeholders Of HilleVax Inc Are Urged By The Schall Law Firm To Participate In The Alleged Securities Fraud Investigation

LOS ANGELES, CA / ACCESSWIRE / July 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Accesswire | 2 years ago
After Plunging -86.93% in 4 Weeks, Here's Why the Trend Might Reverse for HilleVax (HLVX)

After Plunging -86.93% in 4 Weeks, Here's Why the Trend Might Reverse for HilleVax (HLVX)

The heavy selling pressure might have exhausted for HilleVax (HLVX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks | 2 years ago
Stakeholders Of Hillevax Inc Are Encouraged By The Schall Law Firm To Join The Alleged Securities Fraud Investigation

Stakeholders Of Hillevax Inc Are Encouraged By The Schall Law Firm To Join The Alleged Securities Fraud Investigation

LOS ANGELES, CA / ACCESSWIRE / July 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Accesswire | 2 years ago
Stakeholders Of HilleVax Inc Are Encouraged By The Schall Law Firm To Join The Alleged Securities Fraud Investigation

Stakeholders Of HilleVax Inc Are Encouraged By The Schall Law Firm To Join The Alleged Securities Fraud Investigation

LOS ANGELES, CA / ACCESSWIRE / July 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Accesswire | 2 years ago
Stakeholders Of HilleVax Inc Are Encouraged By The Schall Law Firm To Join The Alleged Securities Fraud Investigation

Stakeholders Of HilleVax Inc Are Encouraged By The Schall Law Firm To Join The Alleged Securities Fraud Investigation

LOS ANGELES, CA / ACCESSWIRE / July 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Accesswire | 2 years ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX

NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or the "Company") (NASDAQ:HLVX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Accesswire | 2 years ago
HKVX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into HilleVax, Inc. and Encourages Shareholders to Contact the Firm Today!

HKVX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into HilleVax, Inc. and Encourages Shareholders to Contact the Firm Today!

NEW YORK CITY, NY / ACCESSWIRE / July 23, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX). Investors who purchased HilleVax securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HLVX.

Accesswire | 2 years ago
Stakeholders Of HilleVax Inc Are Encouraged By The Schall Law Firm To Join The Alleged Securities Fraud Investigation

Stakeholders Of HilleVax Inc Are Encouraged By The Schall Law Firm To Join The Alleged Securities Fraud Investigation

LOS ANGELES, CA / ACCESSWIRE / July 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Accesswire | 2 years ago
HKVX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into HilleVax, Inc. and Encourages Shareholders to Contact the Firm Today!

HKVX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into HilleVax, Inc. and Encourages Shareholders to Contact the Firm Today!

NEW YORK CITY, NY / ACCESSWIRE / July 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX). Investors who purchased HilleVax securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HLVX.

Accesswire | 2 years ago
HKVX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into HilleVax, Inc. and Encourages Investors to Contact the Firm Today!

HKVX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into HilleVax, Inc. and Encourages Investors to Contact the Firm Today!

NEW YORK CITY, NY / ACCESSWIRE / July 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX). Investors who purchased HilleVax securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HLVX.

Accesswire | 2 years ago
HilleVax, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights – HLVX

HilleVax, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights – HLVX

NEW YORK, NY / ACCESSWIRE / July 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.

Accesswire | 2 years ago
Loading...
Load More